Anidulafungin: When and how? The clinician's view

Jomy George; Annette C. Reboli

doi:10.1111/j.1439-0507.2011.02052.x

Anidulafungin: When and how? The clinician's view

Jomy George, Annette C. Reboli

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.

Original language	English (US)
Pages (from-to)	36-44
Number of pages	9
Journal	Mycoses
Volume	55
Issue number	1
DOIs	https://doi.org/10.1111/j.1439-0507.2011.02052.x
State	Published - Jan 2012

All Science Journal Classification (ASJC) codes

Dermatology
Infectious Diseases

Access to Document

10.1111/j.1439-0507.2011.02052.x

Cite this

@article{e3900e822f894d67b0b0ae477b252b5a,

title = "Anidulafungin: When and how? The clinician's view",

abstract = "Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.",

author = "Jomy George and Reboli, {Annette C.}",

year = "2012",

month = jan,

doi = "10.1111/j.1439-0507.2011.02052.x",

language = "English (US)",

volume = "55",

pages = "36--44",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Anidulafungin

T2 - When and how? The clinician's view

AU - George, Jomy

AU - Reboli, Annette C.

PY - 2012/1

Y1 - 2012/1

N2 - Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.

AB - Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.

UR - http://www.scopus.com/inward/record.url?scp=82455190843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455190843&partnerID=8YFLogxK

U2 - 10.1111/j.1439-0507.2011.02052.x

DO - 10.1111/j.1439-0507.2011.02052.x

M3 - Review article

C2 - 21668526

AN - SCOPUS:82455190843

SN - 0933-7407

VL - 55

SP - 36

EP - 44

JO - Mycoses

JF - Mycoses

IS - 1

ER -

Anidulafungin: When and how? The clinician's view

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this